HEPA
HEPA clinical trials: Hepion Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Hepion Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 5
- Trials linked
- 5
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
HEPA on the catalyst calendar · HEPA registry changes
- Primary completion May 1, 2023ActualEarly Phase 1NCT05737433Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male SubjectsHepion Pharmaceuticals, Inc. · NASH With FibrosisCompletedHEPALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 15, 2023ActualPhase 2NCT05461105A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3Hepion Pharmaceuticals, Inc. · NASH With FibrosisCompletedHEPALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2025Sponsor estimatePhase 2NCT05402371A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver FibrosisHepion Pharmaceuticals, Inc. · Nonalcoholic Steatohepatitis (NASH)Unknown statusHEPALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 29, 2021ActualPhase 2NCT04480710A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 SubjectsHepion Pharmaceuticals, Inc. · NASH - Nonalcoholic SteatohepatitisCompletedHEPALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2020ActualPhase 1NCT03596697A Study in Healthy VolunteersHepion Pharmaceuticals, Inc. · Hepatitis BCompletedHEPALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner